Effective date
Medicare changes effective July 3, 2025
18 CMS and MAC policy updates take effect on this date across 4 MAC jurisdictions. Every entry links to the government document it came from.
CMS Coverage API · 17
- LCD L38433: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — WPS
LCD-L38433WPSOncologysource ↗
- LCD L38238: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Palmetto GBA
LCD-L38238Palmetto GBAOncologysource ↗
- LCD L38566: MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells — Palmetto GBA
LCD-L38566Palmetto GBAOncologysource ↗
- LCD L38292: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Palmetto GBA
LCD-L38292Palmetto GBAOncologysource ↗
- LCD L38988: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Palmetto GBA
LCD-L38988Palmetto GBAInfectious Disease / Microbiologysource ↗
- LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
LCD-L38985Palmetto GBAOncologysource ↗
- LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
LCD-L39007NoridianOncologysource ↗
- LCD L37824: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Noridian
LCD-L37824NoridianOncologysource ↗
- LCD L39003: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Noridian
LCD-L39003NoridianInfectious Disease / Microbiologysource ↗
- LCD L38649: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — Noridian
LCD-L38649NoridianOncologysource ↗
- LCD L38645: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian
LCD-L38645NoridianOncologysource ↗
- LCD L38341: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian
LCD-L38341NoridianOncologysource ↗
- LCD L38329: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian
LCD-L38329NoridianOncologysource ↗
- LCD L37794: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Palmetto GBA
LCD-L37794Palmetto GBAOncologysource ↗
- LCD L38678: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — WPS
LCD-L38678WPSOncologysource ↗
- LCD L39042: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — WPS
LCD-L39042WPSOncologysource ↗
- LCD L38443: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — WPS
LCD-L38443WPSOncologysource ↗
FDA · 1
- FDA Approval: BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer
FDA-NDA219014NationalHematologysource ↗